Approaches to Neoadjuvant Treatment in Melanoma: A Public Workshop Organized by the FDA and MRA
2021 Update: The Melanoma Research Alliance (MRA) staff in partnership with twenty-one academic co-authors have published a review article: Neoadjuvant Therapy for Melanoma: A U.S. Food and Drug Administration–Melanoma Research Alliance Public Workshop, in Clinical Cancer Research.
The review covers lessons learned from neoadjuvant approaches in breast and lung cancer, and early melanoma trials. The review summarizes potential benefits and risks of neoadjuvant approaches to melanoma, integration with surgery, clinical trial design and regulatory considerations, biomarkers, and challenges and future research directions. This review article provides a succinct summary of neoadjuvant treatments in melanoma.
The article can be freely downloaded here: https://clincancerres.aacrjournals.org/content/27/2/394.long
On November 6, 2019, the FDA and the Melanoma Research Alliance co-hosted a public workshop to identify, discuss, and address key issues, challenges and opportunities in the pursuit of neoadjuvant therapies for patients with surgically resectable melanoma. This exciting, half-day workshop brought together clinicians, researchers, regulators, and patient advocates to explore opportunities and discuss challenges in the development of neoadjuvant therapies for melanoma. The workshop took place at National Harbor (outside of Washington, D.C.) with opportunities to participate in person and via simultaneous webcast.
Keynote Lecture: A role and rationale for neoadjuvant therapy in the melanoma treatment landscape & Session 1: Foundational Experience from Other Areas in Oncology
Session 2: Current Melanoma Neoadjuvant Experience
Session 3: Optimal Clinical Trial Design and Patient Selection
Panel Discussion with Audience Q&A – Working Together to Develop Neoadjuvant Therapies in Melanoma